Accident – Death – Obituary News :
IV Ertapenem Shows Promise in Treating Hidradenitis Suppurativa
Patients suffering from recalcitrant hidradenitis suppurativa (HS) may find hope in a new study that explores the use of IV ertapenem as a treatment option. The research, conducted at the Albert Einstein College of Medicine’s Montefiore HS Center in New York, revealed promising results after administering the antibiotic for an average of 13 weeks.
Study Background and Methodology
The study, led by Dr. Avigdor Nosrati and his team, aimed to investigate the efficacy of IV ertapenem in treating HS, a chronic skin condition characterized by painful lumps under the skin. The researchers conducted a retrospective review of 98 patients’ medical records, tracking their progress before and after receiving the treatment.
Patients included in the study had a mean age of 35.8 years, with a majority being female. The racial distribution of the participants was diverse, with 60.2% identifying as Black/African American, 24.5% as Spanish/Hispanic/Latino, and smaller percentages identifying as White, Asian, or other/unknown.
Key Findings and Results
After analyzing the data, the researchers found that patients who underwent ertapenem therapy experienced improvements in both clinical symptoms and inflammatory markers. Additionally, patient satisfaction levels were notably higher post-treatment, with 80.3% expressing satisfaction with the therapy.
Adverse events associated with IV ertapenem were rare, with only a small percentage of patients reporting mild side effects such as diarrhea, nausea, and headaches. The majority of participants indicated a willingness to undergo another course of therapy and recommended ertapenem to other HS patients.
Implications and Future Directions
The study’s findings suggest that a 12 to 16-week course of IV ertapenem could serve as a new standard length of therapy for HS patients. This extended treatment duration surpasses the current recommendation in North American guidelines, offering a potentially more effective solution for individuals with recalcitrant HS.
Overall, the study sheds light on the promising role of IV antibiotics, specifically ertapenem, in managing HS and improving patient outcomes. As further research is conducted, it is hoped that this treatment approach will continue to evolve, providing relief for those affected by this challenging skin condition.
.